Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan

Anulika Maris Omeaku; Anfal Anwar Sharif; Jameel Malhador Inal; Anulika Maris Omeaku; Anfal Anwar Sharif; Jameel Malhador Inal

doi:10.1155/ecc/3726620

HTML

Rights and permissions

Copyright: © 2026 by the author(s). Exclusive Licensee Maximum Academic Press, Fayetteville, GA. This article is an open access article distributed under Creative Commons Attribution License (CC BY 4.0), visit https://creativecommons.org/licenses/by/4.0/.

About this article

Cite this article

Anulika Maris Omeaku, Anfal Anwar Sharif, Jameel Malhador Inal. 2026. Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan. European Journal of Cancer Care. 2026: doi: 10.1155/ecc/3726620

Anulika Maris Omeaku, Anfal Anwar Sharif, Jameel Malhador Inal. 2026. Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan. European Journal of Cancer Care. 2026: doi: 10.1155/ecc/3726620

{{lists.name}}

Emerging Immunotherapy Options in HER‐2‐Positive Metastatic Breast Cancer: A Meta‐Analysis on Clinical Effectiveness and Safety of T‐DM1, Trastuzumab−Pertuzumab, and Trastuzumab Deruxtecan

Rights and permissions

About this article

Cite this article

Article Metrics

Access History

Other Articles By Authors